Literature DB >> 7883006

Splice variants of the human EP3 receptor for prostaglandin E2.

A Schmid1, K H Thierauch, W D Schleuning, H Dinter.   

Abstract

The EP3 receptor for prostaglandin E2 (PGE2) mediates various biological activities such as uterine contraction, inhibition of gastric acid secretion, presynaptic inhibition of neurotransmitter release and potentiation of platelet aggregation. In an attempt to understand the molecular basis of this diversity of biological function, we cloned full-length cDNAs encoding EP3 receptors for PGE2 from human uterus cDNA libraries. Seven cDNA variants were identified which code for six distinct EP3-receptor isoforms. Sequencing revealed that the receptor isoforms differ in their intracellular C-terminal domains. Southern blot experiments indicate that the isoforms are generated by alternative splicing. The EP3-receptor gene is expressed in various tissues with high expression in kidney and pancreas, as demonstrated by Northern blot analysis. All receptors, stably expressed in baby hamster kidney (BHK) cells, bind PGE2 specifically with similar Kd of 2.2-5.8 nM. The binding of [3H]PGE2 is competed with by unlabelled prostaglandins in the order sulprostone (a PGE2-like agonist) approximately PGE2 >> PGF2 alpha > Iloprost (a prostacyclin analogue) > PGD2, which is specific for EP3 receptors. Analysis of the signal-transduction pathways demonstrated that all receptors respond with inhibition of forskolin-induced cAMP accumulation with an IC50 of 0.1-3 nM PGE2. In addition, some isoforms induce an increase in intracellular free calcium ([Ca2+]i) at PGE2 concentrations greater than or equal to 10 nM. These results may offer an explanation for the different physiological responses observed in various tissues following activation of EP3 receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883006     DOI: 10.1111/j.1432-1033.1995.tb20223.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  23 in total

1.  Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor.

Authors:  M Bastepe; B Ashby
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infection.

Authors:  David M Aronoff; Casey Lewis; Carlos H Serezani; Kathryn A Eaton; Deepti Goel; John C Phipps; Marc Peters-Golden; Peter Mancuso
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

4.  Effect of prostaglandin E2 on multidrug resistance transporters in human placental cells.

Authors:  Clifford W Mason; Gene T Lee; Yafeng Dong; Helen Zhou; Lily He; Carl P Weiner
Journal:  Drug Metab Dispos       Date:  2014-09-26       Impact factor: 3.922

5.  Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation.

Authors:  J E Fabre; M Nguyen; K Athirakul; K Coggins; J D McNeish; S Austin; L K Parise; G A FitzGerald; T M Coffman; B H Koller
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

Review 6.  Prostaglandin E2 receptor distribution and function in the gastrointestinal tract.

Authors:  I Dey; M Lejeune; K Chadee
Journal:  Br J Pharmacol       Date:  2006-10-02       Impact factor: 8.739

Review 7.  A Review of Prostanoid Receptors: Expression, Characterization, Regulation, and Mechanism of Action.

Authors:  Roger G Biringer
Journal:  J Cell Commun Signal       Date:  2020-09-24       Impact factor: 5.782

8.  Cell-specific coupling of PGE2 to different transduction pathways in arginine vasopressin- and glucagon-sensitive segments of the rat renal tubule.

Authors:  L Aarab; S Siaume-Perez; D Chabardès
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

9.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors:  Joshua C Neuman; Michelle E Kimple
Journal:  J Endocrinol Diabetes Obes       Date:  2013 Jul-Sep

10.  Intermolecular cross-talk between the prostaglandin E2 receptor (EP)3 of subtype and thromboxane A(2) receptor signalling in human erythroleukaemic cells.

Authors:  Helen M Reid; B Therese Kinsella
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.